SecBot SecBot
SECBOTREPLAY Home › Report › RLMD

RLMD · Relmada Therapeutics is holding its 2026 annual meeting where…

RELMADA THERAPEUTICS, INC. · DEFA14A filed Apr 17, 2026 at 16:31 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 17, 2026 at 16:31 ET

Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two Class II directors, ratifying the appointment of CBIZ CPAs P.C. as auditors, increasing the number of shares available under its equity incentive plan by 3 million, and increasing its authorized common stock from 150 million to 200 million shares. The filing is a routine proxy statement with no material financial data disclosed.

  • Relmada Therapeutics is holding its 2026 annual meeting
  • Shareholders will vote to elect two Class II directors: Charles J. Casamento and Sergio Traversa
  • Proposal to ratify CBIZ CPAs P.C. as independent auditors for 2026
  • Proposal to increase shares available under the 2021 Equity Incentive Plan by 3 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access